TY - JOUR AU - Yamani, N. S. PY - 2022/01/18 Y2 - 2024/03/29 TI - New Stability Indicating RP-HPLC Method for the Estimation of Budesonide in API and Pharmaceutical Dosage Forms JF - Asian Journal of Pharmaceutics (AJP) JA - AJP VL - 15 IS - 04 SE - ORIGINAL ARTICLES DO - 10.22377/ajp.v15i04.4233 UR - http://www.asiapharmaceutics.info/index.php/ajp/article/view/4233 SP - AB - <p>Introduction: Budesonide is used for the treatment ofchronic obstructive pulmonary diseaseand asthma, and it<br />belongs to glucocorticoid class. A new stability indicating RP-HPLC method has been proposed for the quantification<br />of Budesonide in tablet dosage forms and the method was validated. Materials and Methods: Shimadzu HPLC<br />system with PDA detector was used with Agilent C18 column with mobile phase mixture, formic acid: Methanol<br />(30:70) and flow rate 1.0 ml/min (UV detection at 243 nm). Results and Discussion: Beer-Lambert’s law was<br />obeyed over a concentration range 0.1–100 μg/ml. The linear regression equation was found to be y = 48625x<br />+ 8107.9 (r2 = 0.9998). The LOD and LOQ were found to be and 0.0302 and 0.0922 μg/ml. Stress degradation<br />studies were performed and the method was validated as per ICH guidelines. The proposed method is simple,<br />precise, accurate, and robust and can be applied for the assay Budesonide formulations.</p> ER -